Portola Pharma (PTLA) Misses Q4 EPS by 23c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($1.34), $0.23 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $15.3 million versus the consensus estimate of $10.94 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Ennis (EBF) Reports In-Line Q1 EPS
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)